Core A - Melanoma Biobank The propagation of human cancer cells has been a vital part of cancer biology including the seminal discovery of BRAF mutations in melanoma. Historically, cancer lines have proven to be a powerful system for screening novel therapeutic compounds and for isolating molecular determinants of sensitivity to anti-cancer drugs. The main charge of Core A- the Melanoma Biobank (MBB)- is to establish a critical set of melanoma cell lines from patients who undergo treatment with selective Braf inhibitors or other novel agents. Vital derivatives from Core A, along with annotated specimens, will be available to the rest of the P01 for molecular verification and functional validation of target candidates which may emerge from the various screens.
The Specific Aims of Core A are (1) to provide a central source of melanoma cells obtained prior to initiation of selective Braf inhibitors (SBIs) and during relapse while undergoing treatment, (2) to provide mutational, copy number, expression and pathway actiyation profiles on cell lines and (3) to provide sensitivity data for selective BRAF inhibitors and other targeted therapies and to compare drug responses across various targeted agents and (4) to maintain a clinical database and tissue repository derived from patients on targeted therapy trials. This last Aim will leverage extant funding and will provide a critical piece of the correlative puzzle in the overall translational effort. By the end of the funded period, successful integration of all Projects and Cores within the POI will yield an unprecedented set of tissue specimens and vital cells adorned with meticulous clinical annotation and in-depth molecular profiling.
The use of living cancer cells has been invaluable in our ability to identify new treatments and to test novel drugs. The mission of this Core facility is to maintain a bank of living melanoma cells for careful study and for future drug discovery. The overall goal of the Program Project is to better understand why patients continue to relapse from anti-Braf drugs.
|Alves, Cleidson P; Yokoyama, Satoro; Goedert, Lucas et al. (2016) MYO5A gene is a target of MITF in melanocytes. J Invest Dermatol :|
|Kryukov, Gregory V; Wilson, Frederick H; Ruth, Jason R et al. (2016) MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science 351:1214-8|
|Xia, Yun; Li, Ying; Westover, Kenneth D et al. (2016) Inhibition of Cell Proliferation in an NRAS Mutant Melanoma Cell Line by Combining Sorafenib and Î±-Mangostin. PLoS One 11:e0155217|
|Wang, Hequn; Osseiran, Sam; Igras, Vivien et al. (2016) In vivo coherent Raman imaging of the melanomagenesis-associated pigment pheomelanin. Sci Rep 6:37986|
|Tirosh, Itay; Izar, Benjamin; Prakadan, Sanjay M et al. (2016) Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352:189-96|
|Shen, Che-Hung; Kim, Sun Hye; Trousil, Sebastian et al. (2016) Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma. Nat Med 22:1056-61|
|Friedman, Adam A; Amzallag, Arnaud; Pruteanu-Malinici, Iulian et al. (2015) Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment. PLoS One 10:e0140310|
|Kumar, Raj; Taylor, Michael; Miao, Benchun et al. (2015) BAP1 has a survival role in cutaneous melanoma. J Invest Dermatol 135:1089-97|
|Kwong, Lawrence N; Boland, Genevieve M; Frederick, Dennie T et al. (2015) Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. J Clin Invest 125:1459-70|
|Zheng, Bin; Fisher, David E (2015) Metabolic vulnerability in melanoma: a ME2 (me too) story. J Invest Dermatol 135:657-9|
Showing the most recent 10 out of 49 publications